TFF Pharmaceuticals Inc Ordinary Shares TFFP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TFFP is a good fit for your portfolio.
News
-
TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
-
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
-
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
-
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
-
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
-
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
-
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
-
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Trading Information
- Previous Close Price
- $2.20
- Day Range
- $2.05–2.20
- 52-Week Range
- $1.96–19.75
- Bid/Ask
- $2.09 / $2.44
- Market Cap
- $6.48 Mil
- Volume/Avg
- 13,334 / 36,951
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
- Website
- https://www.tffpharma.com
Valuation
|
Metric
|
TFFP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.54 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TFFP
|
|---|---|
Quick Ratio | 2.43 |
Current Ratio | 3.13 |
Interest Coverage | — |
Quick Ratio
TFFP
Profitability
|
Metric
|
TFFP
|
|---|---|
Return on Assets (Normalized) | −108.41% |
Return on Equity (Normalized) | −119.76% |
Return on Invested Capital (Normalized) | −120.30% |
Return on Assets
TFFP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bcjtflmxgh | Gsxtq | $567.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hjyyqvfk | Qgjkpr | $106.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hxpqngl | Jlnfxq | $105.9 Bil | |
MRNA
| Moderna Inc | Lhtzfppf | Bcprl | $46.4 Bil | |
ARGX
| argenx SE ADR | Jhmtzwlp | Cpjd | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Pdqmwmvnt | Pdpk | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Brdpctjyg | Ntxnhzr | $19.5 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jfylzxhds | Rmwynj | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gqbnftjqcr | Zlywmk | $12.8 Bil | |
INCY
| Incyte Corp | Jqvgqmgw | Vvcqlpc | $12.2 Bil |